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Chromium-Induced Kidney Disease
by Richard RP Wedeen* and Lifen Qiant
Kidney disease is often cited as one of the adverse effects of chromium, yet chronic renal
disease due to occupational or environmental exposure to chromium has not been reported.
Occasional cases ofacute tubularnecrosis (ATN) following massive absorption ofchromate have
been described. Chromate-induced ATN has been extensively studied in experimental animals
followingparenteral administration oflarge doses ofpotassium chromate (hexavalent) (15 mg/kg
body weight). The chromate is selectively accumulated in the convoluted proximal tubule where
necrosis occurs. An adverse long-term effect of low-dose chromium exposure on the kidneys is
suggested by reports of low molecular weight (LMW) proteinuria in chromium workers. Exces-
sive urinary excretion of53-microglobulin, a specific proximal tubule brush border protein, and
retinol-binding protein has been reported among chrome platers and welders. However, LMW
proteinuria occurs after a variety of physiologic stresses, is usually reversible, and cannot by
itself be considered evidence of chronic renal disease. Chromate-induced ATN and LMW
proteinuria in chromium workers, nevertheless, raise the possibility that low-level, long-term
exposure may produce persistent renal injury. The absence of evidence of chromate-induced
chronic renal disease cannot be interpreted as evidence ofthe absence ofsuch injury. Rather, it
must be recognized that no prospective cohort or case-control study ofthe delayed renal effects
oflow-level, long-term exposure to chromium has been published.
Introduction
Recognition ofthe massive deposits ofchromium used
in landfill in Hudson County, New Jersey, has drawn
attention to the potential health hazards of this heavy
metal. Kidney disease is often cited as an adverse effect
of chromium, yet chronic renal disease due to occupa-
tional or environmental exposure to this metal has not
been reported (1). The absence ofevidence ofchromate-
induced chronic renal disease, however, cannot be in-
terpreted to mean that such injury does not occur.
Rather, it must be recognized that no prospective cohort
or case-control study ofthe delayed renal effects oflow-
level, long-term exposure to chromium has been pub-
lished. As early as 1916, the NewJersey Department of
Labor warned that the bichromate in commercial
pigments not only produced ulcers ofthe skin and nasal
septum, but "It also acts upon the digestive tract by
swallowing the dust, upon the pharynx by inhalation,
and upon the kidneys by blood absorption" (2). In 1924,
the NewJersey legislature included chromium poisoning
among the 10 occupational diseases compensable under
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the State's workmen's (now workers') compensation law.
Despite recognition of acute renal failure from chro-
mium over 100 years ago (3), no reliable information is
yet available on the long-term effects of chromium on
the kidney.
Acute Tubular Necrosis
In contrast to the paucity of evidence on chromium-
induced chronic renal disease, massive exposure to
hexavalent chromium consistently causes acute tubular
necrosis (ATN), clinically evident as a marked reduc-
tion in urine flow rate, if the patient survives for more
than a few hours. ATN is characterized by the rapid
onset of renal failure. Following heavy acute absorp-
tion, symptomatology is initially dominated by over-
whelming pulmonary or gastrointestinal toxicity,
depending on the route ofexposure. In the syndrome of
ATN, early oliguria (urine output less than 200 mL/day
in adults) is followed by a polyuric phase (urine output
exceeding 3 L/day), and subsequent gradual recovery
of renal function over a few weeks. Prior to spontane-
ous tubular regeneration and restoration ofrenal func-
tion, hemodialysis may prove life-saving by temporarily
sustaining the patient. ATN caused by massive absorp-
tion ofchromic acid and successful treatment by dialysis
has been reported (3-6). Acute renal failure from acci-
dental exposure to either trivalent or hexavalent chro-
mium in the workplace is, however, distinctly rare.WEDEEN AND QIAN
Potassium chromate, 15 mg/kg body weight given
parenterally, reproducibly induces ATN in animals (7,8).
This experimental model ofacute renal failure has per-
mitted a detailed analysis of the pathophysiology
of nephrotoxic ATN in the rat, using sophisticated
micropuncture, microperfusion, and microdissection
techniques (Fig. 1). Potassium dichromate produces ne-
crosis in the convoluted portion ofthe proximal tubule,
in contrast to mercuric chloride, which causes necrosis
in the more distal straight segments ofproximaltubules.
Cellular necrosis is preceded by impairment ofintracel-
lular enzyme activity and enzymuria (9,10). Restoration
of renal function may be incomplete, leaving residual,
chronic interstitial nephritis in this experimental model
(8). However, no such cases ofincomplete recovery have
been reported in humans leaving persisting chronic in-
terstitial nephritis.
Metabolism
Studies usingradioactive 5ICrplaced intratracheally in
animals indicate chromium is selectively accumulated
in the renal cortex at a 6- to 20-fold higher concentra-
tion than in red blood cells or liver (11). In vitro studies
using rat renal cortical slices support these inferences
(12). Both trivalent and hexavalent chromium are accu-
mulated up to 80-fold above the incubation medium
concentration in the slice preparation by a process that
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FIGURE 1. Functional changes and site oftubular necrosis induced by
potassium chromate in rat. From Biber et al. (7) with permission.
appears to represent active (energy requiring) biologic
transport (12). Renal cortical accumulation ofchromate
demonstrated by low resolution autoradiography ap-
pears to represent uptake in the convoluted portion of
proximal tubules, the site of cellular necrosis (11). Al-
though it is generally agreed that the trivalent form of
chromium is less nephrotoxic than the hexavalent form,
tubular necrosis and acute renal failure have been re-
ported from both species of the metal (5,6,13,14). In
contrast to the trivalent form, hexavalent chromium is
water soluble and readily penetrates cell membranes.
Absorption is less than 1% from the intestinal tract for
both oxidation states (15). While the hexavalent form
facilitates entry into the circulation and cell, cellular
injury is believed to be initiated by intracellular pro-
tein binding ofthe trivalent form.
Tubular Proteinuria
Suggestive evidence that chronic low-dose exposure
to chromium has adverse effects on the kidneys arises
from the finding of low molecular weight (LMW) pro-
teinuria in chromium workers. Excessive urinary
excretion ofP2-microglobulin, a specific proximal tubule
brush border protein (BB-50) and an extra-renal en-
zyme, retinol-binding protein, have been reported among
some chrome platers and welders (Tables 1 and 2), but
not in others (16-18). The reasons forthese contradictory
findings are not clear but may relate to the absence ofa
reliable measure of cumulative past absorption and un-
Table 1. Renal function parameters (17).a
Geometric mean ± SD/g creatinine
BB-50, Albumin, RBP,
Group units mg ,ug
Chromateworkers 5.25 ± 2.34 2.69 ± 1.81 84.2 ± 2.2
Controls I 2.63 ± 1.43* 2.29 ± 1.86 39.8 ± 2.1*
Cisplatin-treatedpatients 104.00 ± 5.62 10.70 ± 8.50 174.0 ± 3.2
Controls II 2.57 ± 2.18t 4.20 ± 2.11 51.2 ± 1.6t
aBB-50,brushborderprotein; RBP,retinol-bindingprotein. Student's
t test for independent samples for difference between controls I and




Table 2. Correlation coefficients between urinary
excretion ofBB-50 and albumin or BB-50 and RBP (17).a
BB-50 and BB-50 and
Group albumin RBP
Chromate workers 0.04 0.44*
Cisplatin-treated patients 0.43* 0.61t
Controls I 0.39* 0.02
Controls II 0.06 0.07
aBB-50, brush borderprotein; RBP, retinol-binding protein.
*p <0.05.
tp<0.01.
F:P EULIN F:P PAH
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certainty about the oxidation state ofchromium because
ofits instability in biological materials.
Urinary LMW proteins may originate from either the
tubule cell (e.g., BB-50 or N-acetylglucosaminidase)
or from outside the kidney (e.g., IB2-microglobulin or
retinol-binding protein). Extra-renal LMW proteins are
filtered at the glomerulus and taken up by endocytosis
at the luminal surface of proximal tubule cells. The in-
tracellular LMW proteins are then catabolized within
lysosomes to constituent amino acids. Filtered LMW
proteins, consequently, do not normally appear in the
urine.
LMW proteinuria indicates tubular dysfunction and
is often called "tubular proteinuria." Such tubular dys-
function is usually reversible and is not considered
indicative ofrenal disease unless it predicts the appear-
ance of renal failure manifested by a decrease in glo-
merular filtration rate. LMW proteinuria has been
shown to predict the later development ofrenal failure
in cadmium nephropathy (19). It has been suggested that
tubular dysfunction may only occur when urinary chro-
mium exceeds 15 ,ug/g creatinine (17). Although it is
apparent that chromium filtered at the glomerulus is
largely reabsorbed by the tubule, renal clearance calcu-
lations are uninterpretable because of the complex
binding characteristics ofthe various chromium species
to serum proteins and the dependence of chromium
excretion on urine flow rates.
Tubular proteinuria, the excretion ofa few milligrams
ofprotein under 20 kDa molecular weight that are nor-
mally not found in the urine, must be distinguished from
classical glomerular proteinuria. Glomerular proteinuria
often exceeds several grams per day and consists of
high molecular weight proteins such as albumin and
globulin. Tubular proteinuria occurs after a wide vari-
ety of physiologic stresses, is usually reversible, and
cannot by itselfbe considered evidence of chronic renal
disease. Progression to renal failure has not been ob-
served among chrome workers exhibiting tubular
proteinuria (17,18). Although acute tubular necrosis in-
duced by single large doses ofchromium is preceded by
tubular proteinuria, there is no evidence that tubular
proteinuria resulting from repeated small doses results
in permanent renal damage, i.e., chronic renal disease.
Chronic Renal Injury
Chromate-induced ATN and tubular proteinuria,
nevertheless, suggest that low-level, long-term expo-
sure to chromium might produce chronic renal injury.
Repeated minor tubular insults would be expected to
eventually result in chronic interstitial nephritis. In
contrast to glomerular disease, which is readily detected
by simple tests forurinary albumin, interstitial nephritis
is difficult to detect before the renal disease has be-
come advanced, that is before more than two-thirds of
kidney function is lost. At this relatively late state, there
is sufficient reduction in the glomerular filtration rate
to be detected by standard laboratory tests: elevation
of the serum urea nitrogen and creatinine concentra-
tion. Immunologically mediated glomerular disease has
been described from low-dose mercuric chloride admin-
istration in genetically susceptible animals, but primary
glomerular disease has not been reported as a conse-
quence of exposure to chromium. Chromium has, how-
ever, been reported to modify the immune system in
animal models (1).
Because of the long delay in appearance, the rela-
tively low attack rate, the difficulty in detecting early
interstitial nephritis, and the multifactorial nature of
kidney disease, chronic renal disease caused by chro-
mium is unlikely to be identified in the usual one-
on-one physician-patient encounter. Rather, systematic,
prospective epidemiologic studies must be undertaken
in which exposed individuals are compared to controls
ofsimilar age, sex, race, and socioeconomic background.
Such a study should have a sensitive measure of cumu-
lative past exposure to chromium as well as measures
of kidney function. Since chromium may accumulate in
kidney tissue over many months (20), and the biological
half-life approximates 1 month (21-23), it may be pos-
sible to develop a chelation test to assess cumulative
absorption comparable to the EDTA lead-mobilization
test that has proven so useful in identifying lead
nephropathy (19). Minor decreases in glomerular filtra-
tion may have to be identified prospectively in rela-
tively large groups of exposed individuals compared to
matched controls. Moreover, the contribution of chro-
mium to renal failure may only be evident when super-
imposed on other causes of renal injury such a lead
nephropathy, hypertension, or diabetes mellitis or as a
reduction in the renal reserve.
Summary
In summary, both trivalent and hexavalent chromium
compounds are selectively accumulated in the proximal
convoluted tubule where, in large dosage, they induce
acute tubular necrosis following parenteral administra-
tion. Coupled with the finding oftubular proteinuria in
chromium workers, there is reason to suspect that
chromium contributes to the development of chronic
renal failure. The absence of reports of chronic renal
disease due to chromium may not indicate the absence
of an adverse renal effect but merely the absence of
adequate clinical and epidemiological investigation.
Despite the advances in our understanding of the
pathogenesis ofrenal disease over the past few decades,
preventable etiologies of chronic renal disease are only
rarely identified. The contribution of environmental
toxins to the progressive reduction in renal function
with aging and systemic disease remains unknown.
Large-scale, prospective case-control epidemiologic
studies may be required to demonstrate the presence
or absence chromium-induced chronic renal disease.
Such an effort may well be worthwhile because
chromium-induced kidney disease is potentially pre-
ventable. In 1988, over 135,000 Americans had end-stage
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renal disease requiring dialysis or transplantation to
sustain life at a cost of over $4.5 billion per year. New
Jersey has the highest prevalence of end-stage renal
disease in the United States (99 per million) (24) as well
as impressive industrial pollution (25). It may therefore
be appropriate to begin efforts at identifying prevent-
able renal disease in this setting.
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